Background: Up to 3% of people worldwide suffer from chronic inflammatory skin condition psoriasis. When combined with risk factors for atherosclerosis, psoriasis may increase the incidence of metabolic syndrome and other cardiovascular diseases. Urotensin II (UII) is a vasoactive peptide that has been suggested to be increased in metabolic syndrome. Aim: It was to analyze the connection between the severity of the illness and the serum level of Urotensin II (UII) in psoriasis patients. Methods: 40 patients with psoriasis and 40 control participants participated in this study; they were age- and sex-matched. The cases underwent a thorough history taking and clinical examination, along with an evaluation of the extent and severity of the psoriasis. All subjects' serum UII and lipid profile were measured using ELISA. Results: The case and control groups' fundamental demographic and clinical data did not statistically differ from one another. When comparing the median level of UII (1.28- 17.35 ng/ml) in control group versus that in patients’ group; the latter showed a statistically higher significant level (p= 0.001) than the control group (26.26 ng/ml). The best urotensin II cutoff point for identifying psoriasis cases from controls was > 12.825 ng/ml, with 97.5 % sensitivity, 90 % specificity, 95% NPV, 97.5 % PPV, and a total accuracy of 92.5 %. With a statistically significant value of p< 0.001, the AUC was 0.987. Conclusion: Based on our findings, Urotensin II could be used to diagnose psoriasis in susceptible people. |
